Pau Montesinos

Research interests

Publications

• Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2023 · 10.1016/s0140-6736(23)00464-6

• Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

  Blood · 2022 · 10.1182/blood.2021014586

• Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2117344

• Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

  Blood · 2022 · https://doi.org/10.1182/blood.2021011583

• Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00494-0

• Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30205-2

• Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004444

• Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

  Blood · 2020 · https://doi.org/10.1182/blood.2020004856

• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

  Blood · 2019 · https://doi.org/10.1182/blood-2019-01-894980

• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30150-0

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902688

• Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

  Leukemia · 2018 · 10.1038/s41375-018-0312-9

• Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

  Blood Advances · 2018 · https://doi.org/10.1182/bloodadvances.2018016121

• Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.52.2425

• International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.52.8562

• How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

  Blood · 2014 · https://doi.org/10.1182/blood-2013-10-512640

• Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

  Blood · 2010 · 10.1182/blood-2010-01-266007

• Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

  Blood · 2010 · https://doi.org/10.1182/blood-2010-04-277434

• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

  Blood · 2008 · https://doi.org/10.1182/blood-2008-05-159632

• Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

  Blood · 2008 · https://doi.org/10.1182/blood-2007-07-100669

• Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

  Blood · 2008 · https://doi.org/10.1182/blood-2008-07-168617

• Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

  Blood · 2007 · https://doi.org/10.1182/blood-2007-07-099978

• Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

  Haematologica · 2007 · https://doi.org/10.3324/haematol.11575

Current projects

No projects listed.